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Background Countries in the World Health Organization (WHO)
European Region are reporting more severe influenza activity in the
2015–2016 season compared to previous seasons.
Objectives To conduct a rapid risk assessment to provide interim
information on the severity of the current influenza season.
Methods Using the WHO manual for rapid risk assessment of
acute public health events and surveillance data available from Flu
News Europe, an assessment of the current influenza season from 28
September 2015 (week 40/2015) up to 31 January 2016 (week 04/
2016) was made compared with the four previous seasons.
Results The current influenza season started around week 51/2015
with higher influenza activity reported in Eastern Europe compared
to Western Europe. There is a strong predominance of influenza A
(H1N1)pdm09 compared to previous seasons, but the virus is
antigenically similar to the strain included in the seasonal influenza
vaccine. Compared to the 2014/2015 season, there was a rapid
increase in the number of severe cases in Eastern European countries
with the majority of such cases occurring among adults aged
<65 years.
Conclusions The current influenza season is characterized by an
early start in Eastern European countries, with indications of a more
severe season. Currently circulating influenza A(H1N1)pdm09
viruses are antigenically similar to those included in the seasonal
influenza vaccine, and the vaccine is expected to be effective.
Authorities should provide information to the public and health
providers about the current influenza season, recommendations for
the treatment of severe disease and effective public health measures
to prevent influenza transmission.
Keywords 2015–2016 Influenza season, influenza A(H1N1)pdm09
virus, seasonal influenza, WHO European Region.
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Introduction
Each year, seasonal influenza is estimated to affect 5–10% of
the world’s population resulting in between 250 000 and
500 000 deaths, as well as causing significant costs to health
services. In the 2014–2015 influenza season, there was an
unusually high excess mortality in the 15 European countries
participating in the European monitoring of excess mortality
for public health action (EuroMOMO).1 An estimated
217 000 premature deaths occurred among the elderly; many
of which are likely to be due to influenza.
Countries conduct influenza surveillance to determine
when and where influenza activity is occurring, detect
changes in the antigenic and genetic characteristics of
seasonal influenza viruses, describe the clinical patterns of
influenza and risk factors for severe disease, assess the relative
severity of the season and detect unusual events due to
influenza.2 In the World Health Organization (WHO)
European Region, this surveillance is coordinated by the
WHO Regional Office for Europe and the European Centre
for Disease Prevention and Control (ECDC) which jointly
publish the weekly influenza update ‘Flu News Europe’
(FNE) between weeks 40 and 20 of each year.3
As part of overall surveillance core capacities under the
InternationalHealth Regulations,4Member States are required
to have risk assessment capacity at national level for acute
public health events.WHO assists countries in performing risk
assessments for events at national level and takes the lead in
conducting risk assessments for multicountry or regional
events. A risk assessment systematically gathers and assesses
information to assign a level of risk to an acute public health
event.5 WHO guidance on how to perform a rapid risk
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assessment (RRA) entitled ‘Rapid risk assessment of public
health events’ recommends assessing the risk, with respect to
the hazard, exposure and context, of an acute public health
event.5 The RRA is performed by addressing the critical risk
questions in order to scope the focus of the risk assessment to
key priority concerns that need immediate public health
measures. Therefore, RRAs are intended to rapidly support
and direct public health decision-making.
The WHO Regional Office for Europe started receiving
reports from a number of Eastern European countries of
severe disease and deaths associated with influenza A(H1N1)
pdm09 in late December 2015, as well as requests for support
(Armenia, Georgia and Ukraine). There was high media
attention and concern among the public in these countries.
To investigate whether the 2015–2016 influenza season could
be amore severe season comparedwith previous seasons, a RRA
was conducted among the 50 of the 53 Member States of the
WHO European Region which provide data to FNE.
Materials and methods
The RRA was conducted using the WHO manual ‘Rapid risk
assessment of acute public health events’ according to a list of
risk questions (Table 1).5 It is based on data available on
FNE between 28 September 2015 (week 40/2015) and up to
31 January 2016 (week 04/2016) as well as historical data
from 4 previous influenza seasons (i.e. the 2011–2012, 2012–
2013, 2013–2014 and 2014–2015 influenza seasons). It
includes information from the WHO risk assessment –
seasonal influenza A(H1N1)pdm09 published on 8 February
2016 – and the ECDC risk assessment – seasonal influenza
2015–2016 in the EU/EEA countries published on 8 February
2016.6,7 The WHO recommendations arising from this RRA
have already been published to support timely and appro-
priate control measures in Member States of the WHO
European Region.
The WHO European Region consists of 53 Member States,
of which 50 have surveillance systems for seasonal influenza.
National influenza focal points report data on influenza to
FNE through the ECDC platform The European Surveillance
System (TESSy) on a weekly basis during the influenza
surveillance season (week 40 to week 20 of each year). Data
sources vary by country, but include sentinel and non-sentinel
surveillance systems for influenza-like illness (ILI), acute
respiratory infections (ARI), severe acute respiratory infec-
tions (SARI) and/or influenza-confirmed hospitalized cases.3
Table 1. Overview risk assessment
Component (definition) Key output Risk questions
Hazard (identification of a potential
hazard that causes the event with
adverse effects)
Viral factors Is there a higher proportion of influenza A(H1N1)pdm09
versus influenza A(H3N2) and influenza B compared with previous seasons?
Is there evidence that currently circulating influenza A(H1N1)pdm09 viruses have
changed antigenically compared with the vaccine virus, or acquired mutations
that would result in increased virulence or severity of disease?
Is there evidence of reduced susceptibility to the neuraminidase inhibitors
oseltamivir and zanamivir of currently circulating A(H1N1)pdm09 viruses?
Clinical factors Is a particular virus more frequently associated with severe infection?
Exposure (evaluation of the exposure
of individuals to potential hazards)
Epidemiology of infection Is there evidence of a more severe season?
Is there a difference in the age groups that are severely affected this season?
Is this season associated with a higher frequency of severe outcomes?
Susceptibility Is there a difference in age groups that are severely affected this season?
Is there a difference in age groups with/without comorbidities that are severely
affected this season?
Population immunity In countries experiencing a severe season, are there more persons affected,
or affected severely, compared with other countries due to the fact that there
are still people that have not been infected with the A(H1N1)pdm09 virus?
Vaccine effectiveness Is there evidence of reduced vaccine effectiveness?
Transmission Is the start of the season earlier than usual/unusually earlier?
Are there unusually high levels of influenza activity in the community?
Context (evaluation of the
environment of the event)
Socio-economic Are there socio-economic factors that could result in an increase in severe
disease this season? Are vulnerable or displaced persons affected?
Programmatic Are there more severe cases in some countries due to weak health systems or
political or other crisis?
Could reports of severity in some countries be (partly) explained by changes in
surveillance practices due to media attention/concerns of the public?
Based on the WHO manual ‘Rapid risk assessment of acute public health events’.5
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Epidemiological and virological influenza data were
included in the current analysis.
Where appropriate, we grouped countries into Southern,
Northern, Eastern and Western Europe, as well as Central
and Western Asia subregions, according to United Nations
geographic classification (Figure 1).8
Hazard assessment
Data available from FNE were assessed to answer risk
questions related to viral factors and clinical factors associ-
ated with the specific hazard.
Viral factors included potential antigenic drift compared
to the vaccine strains; acquired genetic mutations that could
be associated with increased virulence, including evidence of
antiviral resistance, based on data available for 20 countries,
representing all subregions except Western and Central
Asia.
The proportion of A(H1N1)pdm09 viruses among total
sentinel ILI and ARI detections and non-sentinel detec-
tions were analysed for the WHO European Region and
for the six subregions from week 40/2015 to week 04/
2016 of this season. The proportion of A(H1N1)
pdm09 viruses among total sentinel ILI and ARI detections
from week 40/2015 to week 04/2016 of this season was
compared to the same time period from the last four
seasons.
Exposure assessment
In order to assess the epidemiology of the infection, we
evaluated the severity of the current season compared with
previous seasons for all countries for which it was considered
that the season had started. As not all countries had a
threshold/baseline for influenza activity, we were unable to
use this to assess the start of the season and used instead the
criterion of at least five consecutive weeks of increasing
influenza activity according to the influenza-like illness (ILI)
or acute respiratory infections (ARI) consultation rates. All
countries reporting severe acute respiratory infections (SARI)
from sentinel hospitals or laboratory-confirmed influenza in
hospitalized patients were assessed. In total, data from 26
countries were used for this study (Table 2).
We evaluated the trend (i.e. increases and decreases) of
influenza activity for ILI, ARI and SARI compared with the
four previous seasons. Also, we compared SARI rates for this
season with the previous season (2014–2015) with respect to
the number of cases by age groups, influenza virus type and
subtype among cases and the percentage of SARI cases
positive for influenza for this and the previous season. The
number of cases, the age groups and the subtyped viruses for
hospitalized patients with laboratory-confirmed influenza
were also evaluated.
Data for mortality were available through the European
monitoring of excess mortality for public health action
Subregions
Central Asia
Eastern Europe
Northern Europe
Southern Europe
Western Europe
West Asia
Figure 1. Subregions of the WHO European Region, according to the United Nations geographic composition. *WHO European Region Member States
that participate in influenza surveillance grouped into subregions according to United Nations geographic composition (http://unstats.un.org/UNSD/
METHODS/M49/M49REGIN.HTM): Western Europe (Austria, Belgium, France, Germany, Luxembourg, Monaco, the Netherlands, Switzerland); Northern
Europe (Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, United Kingdom); Southern Europe (Albania, Bosnia and
Herzegovina, Croatia, Greece, Italy, Malta, Montenegro, Portugal, Serbia, Slovenia, Spain, The former Yugoslav Republic of Macedonia); Western Asia
(Armenia, Azerbaijan, Cyprus, Georgia, Israel, Turkey); Eastern Europe (Belarus, Bulgaria, Czech Republic, Hungary, Poland, Republic of Moldova,
Romania, Russian Federation, Slovakia, Ukraine); Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan).
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(EuroMOMO), a mortality monitoring system aimed at
detecting and measuring excess all-cause mortality in real
time (weekly) during the influenza season.9
Neither data on population immunity to seasonal
influenza A(H1N1)pdm09 nor data on vaccine coverage
were available publicly for the 2015–2016 season for all
countries in the WHO European Region. In order to evaluate
the possible impact of seasonal influenza vaccine coverage on
the severity of the 2015–2016 season in all 53 Member States,
published data on seasonal influenza vaccine coverage from
the 2008–2009 and 2009–2010 seasons as well as unpublished
data were evaluated 10 (WHO: unpublished data). Interim
data on vaccine effectiveness from the Influenza Monitoring
Vaccine Effectiveness (I-MOVE) project for this season (EU/
EEA countries only) are also discussed.11
Context assessment
Information on surveillance practices in countries reporting
sentinel SARI cases is discussed. However, information on
socio-economic factors that could result in an increase in
severe disease this season, or on the extent to which
vulnerable or displaced persons may be more severely
affected, was not available.
Results
Hazard assessment
Viral factors
Since week 40/2015 until week 4/2016, 227 572 specimens
have been tested from sentinel and non-sentinel sources in
the WHO European Region, of which 14% have tested
positive for the influenza virus; 85% of the influenza virus-
positive specimens from sentinel sources and 94% of those
from non-sentinel sources contained influenza A viruses,
with a strong predominance of A(H1N1)pdm09 among the
viruses subtyped (84% from the sentinel sources and 91%
from the non-sentinel sources).
Table 2. List of countries used in the analyses performed for this study (for influenza-like illness (ILI), acute respiratory infections (ARI), severe acute
respiratory infections (SARI) and/or laboratory-confirmed hospitalized cases)
Name of country
Influenza-like
illness (ILI)
Acute respiratory
infections (ARI)
Severe acute respiratory
infections (SARI)
Laboratory-confirmed
hospitalized cases
Albania U U
Armenia U U U
Azerbaijan U U
Belarus U U U
Estonia U U
Finland U U U
France U U
Georgia U U
Greece U
Ireland U U
Israel U
Italy U
Kazakhstan U U U
Kyrgyzstan U U U
Portugal U
Republic of Moldova U U U
Romania U U U
Russian Federation U U U
Serbia U U
Slovakia U U U
Spain U U
Sweden U
Switzerland U
Turkey U
Ukraine U U U
United Kingdom
England U U U
Northern Ireland U U
Scotland U U
Wales U
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The proportion of A(H1N1)pdm09 viruses among total
subtyped sentinel ILI/ARI specimens exceeded 50% in all
weeks between weeks 49/2015 and 04/2016, with the highest
proportion (70%) reported in week 52/2015. During four
previous seasons, a proportion of A(H1N1)pdm09 of more
than 50% was reported in one week only, namely week 03/
2014, while for the other three seasons, the proportion of A
(H1N1)pdm09 remained below 40% between weeks 49 and
4 (Figure 2).
This season, there are geographic differences in the
proportion of influenza A and B virus types and subtypes
that were reported (Table 3). All geographic subregions
reported predominantly influenza A, and of influenza A
subtyped viruses, the A(H1N1)pdm09 were predominant.
However, Western Europe reported 60% influenza A and
40% influenza B, while the other subregions reported
between 89–100% A. Southern, Eastern, Northern Europe
and Central Asia reported between 89–97% A(H1N1)pdm09.
Western Asia reported the largest proportion of A(H3N2)
(26%) among A subtyped viruses (Table 3).
Across the region, 11% of viruses were influenza B.
Although lineage determination was performed on only a
subset of influenza B viruses, the Victoria lineage was
dominant (85% of the total number of lineage-determined
specimens positive for influenza type B). Of the 3627
influenza B detections reported between week 40/2015 and
week 04/2016, the B-Victoria lineage was assigned to 431
viruses and the B-Yamagata lineage to 75 (Table 3).
Antigenic characterization data from 447 influenza viruses
reported by National Influenza Centres (NICs; data were
available from all subregions except Western and Central
Asia) to FNE showed that the majority (95%) of these were
similar to the viruses recommended for trivalent and
quadrivalent vaccines for use in the 2015–2016 influenza
season. This included all 381 antigenically characterized A
(H1N1)pdm09 viruses.
So far this season, phylogenetic analysis of the haemag-
glutinin (HA) of A(H1N1)pdm09 viruses demonstrated that
these viruses belong to genetic subgroup 6B, in common with
most A(H1N1)pdm09 viruses characterized from more than
30 countries worldwide since September 2015.6
Of the 466 A(H1N1)pdm09, 55 A(H3N2) and 47 type B
viruses tested for neuraminidase inhibitor susceptibility since
week 40/2015, only two A(H1N1)pdm09 viruses showed
highly reduced inhibition by oseltamivir associated with NA-
H275Y amino acid substitution; the remainder showed no
molecular or phenotypic evidence of reduced inhibition by
neuraminidase inhibitors.
Clinical factors
Of the subtyped influenza A viruses, in countries reporting
SARI as well as laboratory-confirmed influenza in hospitalized
or intensive care units, the vast majority were influenza A
(H1N1)pdm09. Of the 564 influenza A viruses that have been
subtyped, there is a predominance of A(H1N1)pdm09 viruses
this season in influenza-confirmed hospitalized cases (Finland,
France, Ireland, Romania, Slovakia, Spain, Sweden andUnited
Kingdom – England) (96%, range 92–100%). For France and
Ireland, there was also an influenza B cocirculation in
influenza-confirmed hospitalized cases this season, and the
proportion of influenza B was 20% and 38%, respectively.
Exposure assessment
Epidemiology of infection
Five countries (Armenia, Georgia, Russian Federation, Serbia
and Ukraine) reporting data on SARI cases had sufficient
data for comparison with the 2014–2015 season. Up until
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Figure 2. Proportion of A(H1N1)pdm09
among subtyped influenza viruses for sentinel
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>10 detections; week 53/2015 is excluded
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week 4/2016, there was an increase in severe disease (SARI
cases) compared to 2014–2015. The number of SARI cases
increased in all age groups compared with the previous
season, but the proportion of adults younger than 65 rose
and shows a slightly different trend compared to the 2014–
2015 season (Figure 3A).
Only five of the eight countries that report on influenza-
confirmed hospitalized cases had data on age groups for this
and the previous season (Spain, France, Ireland, Romania
and Sweden). For this season, the majority of cases are in
those aged 20–64, while last season this was the 65 and older
group (Figure 3B).
However, data on mortality from the 18 EU/EEA countries
and regions in Western, Northern and Southern Europe that
report to EuroMOMO show that so far this season, there have
beenno indicationsof an increase in excess all-causemortality.9
Susceptibility
Seven of eight countries reporting influenza-confirmed
hospitalized cases had data on underlying comorbidities.
However, this amounted to only 14% of cases, precluding
further analysis.
Population immunity and vaccine effectiveness
Currently available data on seasonal influenza vaccine
policies and coverage in all 53 Member States show low
coverage in the elderly among many countries (WHO:
unpublished data).10 The vaccination coverage target of 75%
in the elderly population by 2010 was achieved by two
countries (the Netherlands and United Kingdom – Northern
Ireland and Scotland).12 Furthermore, mechanisms to mon-
itor vaccination coverage in target groups other than the
elderly are lacking in many countries, impeding accurate
assessment of the impact of national influenza vaccination
programmes on the 2015–2016 influenza season.
Interim estimates of influenza vaccine effectiveness in
Europe published recently by the I-MOVE Project show an
adjusted vaccine effectiveness of 463%(95%CI: 49–697%).11
Table 3. Distribution of influenza detections in the WHO European Region: 2015–2016 season (weeks 40/2015 to 04/2016)
Influenza detections*
Southern
Europe
Western
Europe
Eastern
Europe
Northern
Europe West Asia Central Asia
WHO
European
Region
Influenza A 3355 91% 1789 60% 8104 98% 10 001 89% 5926 89% 455 100% 29 630 89%
Influenza A subtyped 2308 966 7464 4117 5899 352 21 106
A (H1N1)pdm09 2069 90% 836 87% 7207 97% 3959 96% 4372 74% 312 89% 18 755 89%
A (H3N2) 239 10% 130 13% 257 3% 158 4% 1527 26% 40 11% 2351 11%
Influenza B 319 9% 1177 40% 135 2% 1232 11% 764 11% 0 0% 3627 11%
B lineage determined 67 232 22 185 0 0 506
B-Yamagata lineage 6 9% 14 6% 6 27% 49 26% 0 0 75 15%
B-Victoria lineage 61 91% 218 94% 16 73% 136 74% 0 0 431 85%
Total 3674 2966 8239 11 233 6690 455 33 257
*Combined ILI, ARI sentinel and non-sentinel respiratory specimens positive for influenza.
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Figure 3. (A) Age groups of SARI cases for the 2014–2015 and 2015–
2016 season week 20 to week 4. (B) Age groups of influenza-confirmed
hospitalized cases for the 2014–2015 and 2015–2016 season week 40 to
week 4.
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Transmission
Using a threshold of ten per cent influenza positive among
specimens from sentinel surveillance sources for the WHO
European Region, the season started in week 51/2015; 46% of
the Member States were reporting low-intensity influenza
activity in week 4/2016, which was similar to the previous
season when 50% of countries reported low-intensity
influenza activity for week 4/2015 (Figure S1). When
comparing the influenza intensity reported in week 4 for
this season with the previous season, there was a variation by
subregion. For Southern and Western Europe, there was low-
intensity influenza activity with 93% of countries reporting
medium- to high-intensity influenza activity for 2014–2015
and 53% for 2015–2016. More countries reported medium-
to very high-intensity influenza activity in Eastern and
Northern Europe and Western Asia (32% of countries for
2014–2015 and 65% for 2015–2016). Reports by Central
Asian countries showed a trend similar to last season, only
reporting low-intensity influenza activity.
When examining the ILI and/or ARI consultation rates for
this season, these were similar compared with previous
seasons. In five countries reporting SARI (Armenia, Georgia,
Russian Federation, Serbia and Ukraine), the increase in
SARI cases was steeper and occurred between three to six
weeks earlier than the previous season. The trend of influenza
activity is illustrated in Figure 4 for a selection of countries
from each subregion.
Context assessment
Regarding surveillance practices, of the five countries from
which SARI data were evaluated, three (Armenia, Georgia and
Russian Federation) collect respiratory specimens from most
or all SARI cases during an influenza season, one (Serbia)
adjusts the sampling strategy according to the capacities of the
NIC and one (Ukraine) has a specified sampling strategy.13
Informal reports from two countries described backlogs in
testing due to a much larger number of specimens being
collected from SARI cases compared with the previous 2014–
2015 season. Information on socio-economic factors that
could result in an increase in severe disease this season, or on
the extent to which vulnerable or displaced persons may be
more severely affected, was not available.
Discussion and conclusions
Main conclusion
In this risk assessment, we evaluated the hazard, exposure
and context of seasonal influenza for the start of the
2015–2016 season to assess whether there are indications
that this will be a more severe influenza season in compar-
ison with previous season(s). This risk assessment showed
that up to week 4/2016, there is a very high predominance of
influenza A(H1N1)pdm09, particularly in Eastern Europe,
but that these viruses are antigenically similar to the virus
included in the 2015–2016 Northern Hemisphere seasonal
influenza vaccines and are susceptible to neuraminidase
inhibitors. Genetic changes observed in currently circulating
A(H1N1)pdm09 viruses are being monitored closely by the
WHO GISRS. Furthermore, the season seems to have started
earlier in Eastern European countries, which is different to a
west–east spread pattern seen in several previous seasons.14
Also, a sharper rise in severe cases was seen in these countries
compared with the previous season. In the WHO European
Region, influenza A(H1N1)pdm09 was associated with severe
disease in all age groups. In line with previous findings when
A(H1N1)pdm09 is circulating throughout the region, severe
cases occurred in greater numbers in adults under 65 years
compared with the previous season.
Strengths and limitations
We performed a rapid but in-depth risk assessment of the
severity of the current influenza season for the WHO
European Region. Although the data originate from a
diversity of influenza surveillance systems, and some data
gaps and quality issues prevented analysis of some data sets,
work carried out in close collaboration with the influenza
network in the WHO European Region on surveillance
standards and country profiles allowed for improved inter-
pretation of the data over the years.2,15
This RRA is based on interim data and reflects the current
risk in the WHO European Region. However, because the
2015–2016 influenza season is still ongoing, it is difficult to
predict the extent or impact of the remainder of the season.
This will need to be evaluated as additional data emerge.
We found the WHO risk assessment methodology useful
to rapidly assess the risk of the current influenza season. The
risk questions that formed the basis for the risk assessment
can be adapted as a season progresses, for future influenza
seasons and in an influenza pandemic. Questions that could
not be answered for this risk assessment, for example the
presence or absence of risk factors in persons with severe
disease, highlighted some gaps in surveillance, which will be
useful to inform future collaboration on influenza surveil-
lance in the WHO European Region.
Hazard
The current influenza season has shown a very high
proportion of influenza A(H1N1)pdm09 viruses across
most of the WHO European Region so far, which was
higher than during the same period of the four previous
seasons.
The WHO has recommended that trivalent vaccines for
use in the 2015–2016 influenza season in the Northern
Hemisphere contain an A/California/7/2009 (H1N1)pdm09-
like virus, an A/Switzerland/9715293/2013 (H3N2)-like virus
and a B/Phuket/3073/2013-like virus.16 So far, there is no
Tjon-Kon-Fat et al.
242 ª 2016 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
evidence that currently circulating influenza viruses have
changed antigenically compared with the vaccine virus.
However, of those influenza B viruses for which the lineage
has been determined, the predominant lineage is Victoria,
which is recommended for inclusion in quadrivalent seasonal
influenza vaccines, but not in trivalent vaccines.
Furthermore, we find no evidence, so far, of reduced
susceptibility of the influenza viruses from the European
Region to the neuraminidase inhibitors oseltamivir and
zanamivir.3
Exposure
The current influenza season in the WHO European Region
started around week 51/2015, which is similar to previous
seasons. Higher influenza activity reported in countries of
Eastern and Northern Europe and Western Asia could
suggest a different pattern of spread than the west–east
spread seen in previous seasons. Of the 5 countries reporting
earlier rises in SARI cases compared with the 2014–2015
influenza season, cases peaked first in Armenia in week 01/
2016, a country neighbouring the Islamic Republic of Iran
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Figure 4. (A and B) Influenza activity for a selection of countries of different subregions (ILI or ARI, SARI and graph of sentinel detections). *For ILI and
ARI, the rates are presented per 100 000 population. Black is the 2015–2016 season, purple 2014–2015, green 2014–2014, red 2012–2013 and blue
2011–2012. ** For SARI, the number of SARI cases is presented. Black is the 2015–2016 season, and purple is the 2014–2015 season. *** For the graphs
on per cent positive, we have used the graphs available on Flu News Europe that have data until week 5.
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which is also experiencing a season predominated by A
(H1N1)pdm09 and in which influenza virus detections
peaked in week 50/2015. This could support an alternative
geographic pattern of spread, possibly from Southern Asia
into countries of the WHO European Region this season.17
A slightly earlier rise than seen in recent years in severe
cases may have caused heightened concern in the affected
countries leading to reports of a more severe season.
However, as these results are interim and as the current
season is still ongoing, it is not possible to say whether this
season will be more severe (i.e. increase in the total number
of severe cases) compared to the previous season.
This season, influenza A(H1N1)pdm09 was associated
with severe disease in all age groups. However, in countries
reporting sentinel SARI cases and/or laboratory-confirmed
influenza in hospitals and intensive care units this season, the
majority occurred in adults younger than 65 years. This is
similar to what has been reported previously for this virus.
Information on comorbidities was only available for a few
cases in the region this season, so no further analysis could be
performed. However, in the USA, in which influenza A
(H1N1)pdm09 is predominating this season, preliminary
clinical findings from the Influenza Hospitalization Surveil-
lance Network based on 349 (389%) cases show that the
majority (907%) of hospitalized adults (≥18 years) had at
least one reported underlying medical condition; the most
commonly reported were cardiovascular disease, metabolic
disorders and obesity.18
Historically, the uptake of seasonal influenza vaccine varies
considerably in countries of the WHO European Region,
being generally lower among the elderly in Eastern versus
Western European countries. For other risk groups, few
countries have systems in place to monitor vaccine uptake.10
Low vaccination uptake may increase the risk of persons
experiencing complications following influenza infection and
contribute to a more severe season in some countries.
Interim estimates of influenza vaccine effectiveness in
Europe published recently by the I-MOVE are of moderate
vaccine effectiveness.11 However, these are interim results
based on a small sample size and should be interpreted with
caution. More accurate estimates are expected to be available
at the end of the season.
Context
At least two countries reporting SARI cases experienced a
backlog in testing due to a much larger number of specimens
being collected compared with the previous 2014–2015
season. Although this did not affect the interpretation of
data for this RRA, it would prohibit assessing in real time the
proportion of SARI cases that are positive for influenza and
whether this was due to a change in adherence by clinicians
to the SARI case definition. Such changes in surveillance
practice might be fuelled by media reports of a severe season
due to a more virulent A(H1N1)pdm09 virus and public
concerns.
Conclusions and recommendations
In conclusion, a possibly earlier start of the season in Eastern
European countries, a sharper rise in severe cases and a
higher proportion of adults aged <65 years frequently
affected led to a more severe start to the season in Eastern
European countries. As the season is ongoing, it is difficult to
say whether this will be a more severe season compared with
the previous seasons for the WHO European Region. So far,
there are indications that due to a predominance of influenza
A(H1N1)pdm09 seasonal influenza this season, there was a
slightly earlier and more severe start of influenza season in
Eastern Europe.
A full list of WHO recommendations concerning
seasonal influenza is available on the WHO website.19
Healthcare personnel should suspect influenza in persons
at higher risk of developing severe disease due to influenza
(pregnant women, individuals with certain chronic dis-
eases, elderly persons, residents of institutions for older
persons and the disabled and children under the age of five
years) who present with a clinically compatible illness;
sufficient influenza antiviral drugs should be available for
treatment. Furthermore, as there is a high predominance of
A(H1N1)pdm09, they should have a higher index of
suspicion for influenza A(H1N1) when adults younger than
65 present to the healthcare services with severe respiratory
disease. Particularly in countries in which the season has
not yet started or peaked, it is recommended to provide
risk groups with seasonal influenza vaccine. To better
inform public health actions during the influenza season,
Member States are encouraged to strengthen their existing
surveillance systems and existing emergency response
capacities.
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